Wegovy obesity drug maker Novo Nordisk increases full year outlook
Sales and profit ahead of expectationsFull year outlook raisedWegovy demand outstripping supplyDanish pharmaceutical giant Novo Nordisk (NOVO-B:CPH), known for its leading weight-loss drug Wegovy, delivered better than expected first quarter sales and earnings and raised its full year profit outlook.After initially opening higher the shares fell back 2% on worries over lower pricing of Wegovy in t